The drug is a protease inhibitor, a class of drugs that work by inhibiting the enzymes the virus needs to replicate in human cells. The type of drug is used to treat other viruses, such as HIV and hepatitis C, according to CNBC, and Pfizer started clinical trials of the drug against COVID-19 in March.
Health experts told CNBC that the drug could be a game changer because it could keep people newly infected with COVID-19 out of hospitals.
Pfizer is also testing an intravenous protease inhibitor drug for patients hospitalized with COVID-19.
Read the full article here.
More articles on pharmacy:
New HHS guidelines allow nearly all healthcare providers to prescribe buprenorphine
Where are COVID-19 vaccination rates dropping the most?
US to share entire AstraZeneca COVID-19 vaccine supply with other nations
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
